VYGR · NASDAQ
Voyager Therapeutics, Inc.
$1.80 +0.05 (+2.56%)
Company overview
Voyager Therapeutics, Inc. is a gene therapy company focused on developing treatments and next-generation platform technologies. Its lead clinical candidate, VY-AADC, is in an open-label Phase 1 clinical trial for Parkinson's disease. The company's preclinical programs include VY-SOD102 for amyotrophic lateral sclerosis, VY-HTT01 for Huntington's disease, VY-FXN01 for Friedreich's ataxia, and a Tau program for tauopathies including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. Voyager has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma AG for the research, development, and commercialization of adeno-associated virus gene therapy products. Founded in 2013, the company is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $111M
- Employees
- 172
- Headquarters
- Lexington, MA
- Website
- voyagertherapeutics.com
- CEO
- Alfred W. Sandrock Jr.
- Listed
- November 11, 2015
- P/E
- -0.91
- Dividend yield
- 0.00%
Company financials
- Revenue
- $36.5M
- Gross profit
- $35.6M
- Operating income
- -$127M
- EBITDA
- -$121M
- Net income
- -$117M
- EPS
- -$1.98
- Total assets
- $219M
- Total debt
- $34.6M
- Gross margin
- 97.45%
- Net margin
- -319.61%
- Earnings yield
- -110.00%
VYGR
1D
NASDAQ
O1.76H1.77L1.71C1.76+0.01 (+0.86%)Vol438.93K